About us
Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for the screening and profiling of kinases in relevant cells and tissues.
Cellzome's emerging pipeline includes a small molecule Histamine H4 receptor antagonist, initially for asthma and allergic rhinitis, which is planned to begin clinical studies in 2008. Cellzome is applying its distinctive Kinobeads™ technology to the discovery and development of novel, selective, kinase inhibitors targeting key inflammatory mediators in immune receptor signaling and chemotaxis, including PI3Kγ and Zap-70.
Cellzome's business strategy is to generate shareholder value by:
- Developing a pipeline of small molecule pharmaceuticals, initially for inflammatory disease
- Collaborating with leading pharma companies in return for research payments, milestone payments, and royalties on sales.
The management team has strong scientific and commercial credentials, and is backed by some of the biotech industry's most experienced investors. Cellzome is intent on developing both organically and through merger or acquisition, whilst maintaining its » values of transparency, commitment and mutual respect.
Cellzome's holding company is domiciled in the US and it employs about 90 people at its two operating subsidiaries in Cambridge, UK and Heidelberg, Germany. [» Cellzome at Glance]